Journal article 13 views
Metabolic biomarkers of appetite control in Parkinson's disease patients with and without cognitive impairment
Mario Siervo,
Fionnuala Johnston,
Emily Calton,
Anthony James,
Blossom C M Stephan,
Amanda Hornsby,
Jeffrey Davies 
,
David Burn
,
David Burn
Clinical Nutrition ESPEN, Volume: 64, Pages: 425 - 434
Swansea University Authors:
Amanda Hornsby, Jeffrey Davies
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1016/j.clnesp.2024.10.167
Abstract
Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions...
| Published in: | Clinical Nutrition ESPEN |
|---|---|
| ISSN: | 2405-4577 |
| Published: |
Elsevier BV
2024
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa68584 |
| Abstract: |
Appetite dysregulation in Parkinson's Disease (PD) appears to be linked to physical and cognitive deterioration. PD patients with and without cognitive impairment (CI) were compared to an age-matched control group to explore predictors of appetite control in fasting and post-prandial conditions. Fifty-five patients were recruited and divided into three groups: twenty controls (age: 74 y, BMI: 25.8 kg/m ), nineteen PD patients without CI (72.5 y, 25.1 kg/m ) and sixteen PD patients with CI (74.3 y, 24.0 kg/m ). Self-reported appetite perception and circulating blood metabolic biomarkers were measured in fasting and over a 3-h post-prandial period. Biomarkers included glucose, insulin, tumour necrosis factor alpha (TNF-α), leptin, acyl-ghrelin, total ghrelin, peptide YY (PYY), glucagon like peptide 1 (GLP-1), insulin growth factor 1 (IGF-1), growth factor (GF) and triglycerides. Patients were then provided with a mixed meal to eat ad libitum with the aim to evaluate links between metabolic biomarkers and control of energy intake. PD patients with CI had a significant lower protein intake (7.4 ± 2.5 g, p = 0.01) compared to controls (21.9 ± 3.1 g) and PD patients without CI (14.3 ± 3.0 g). Post-prandial plasma GLP-1 concentrations were associated with decreased hunger perception (B±SE, -5.3 ± 2.4 mm·h , p = 0.04). PYY concentrations were significantly associated with GLP-1 in fasting (r = 0.40, p = 0.005) and post-prandial (r = 0.46, p < 0.001) conditions. In a multivariate model, post-prandial PYY concentrations were a significant predictor of ad libitum energy intake in all subjects (B±SE, -87.5 ± 34.9 kcal, p = 0.01) and in patients with PD (B±SE, -106.8 ± 44.9 kcal, p = 0.04). PYY and GLP-1 appeared to influence appetite control in PD patients and their roles merit further investigation. |
|---|---|
| Keywords: |
Parkinson disease; Cognitive function; Energy intake; Biomarkers; GLP-1; PYY |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
This study was funded by Newcastle NIHR Biomedical Research Unit. |
| Start Page: |
425 |
| End Page: |
434 |